In recent years, immune checkpoint blocking (ICB) therapy, specifically antibodies against programmed cell death 1 (PD1)/ programmed cell death-Ligand 1 (PD-L1) signaling, has been widely used in cancer, which greatly prolongs the survival time of cancer patients [3]. The gene discussed is PDCD1; the disease is cancer.